Pinion Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy for HPV-16 Cervical Precancer
NORTH BETHESDA, Md. — Pinion Immunotherapeutics has published preclinical data supporting ARV-2001, its lead RNA immunotherapy, in the peer-reviewed journal Vaccines. With an Investigational New Drug application cleared by the FDA, Pinion is ready to begin clinical development for women with HPV-16-positive high-grade cervical precancer (CIN2/3). ARV-2001 is designed to clear precancerous lesions without surgery […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 17 minutes later, on .
Signal breakdown
CurrentWire ranked this story 65.8 of 100 in the snapshot this page was rendered from.
- Freshness
- 31.3 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 10 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: geographic relevance, 10 of 10. How each signal is calculated.
Filed under Health · United States · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: FDA (3), Immunotherapeutics Publishes Preclinical Data Supporting Clinical-Ready RNA Immunotherapy (none), Cervical Precancer (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.